‘Pleasantly surprised’: Subcutaneous infliximab effective, regardless of Crohn’s location (Healio)

New data are challenging a long-held assumption in Crohn’s disease care: that ileal disease is harder to treat than colonic involvement. A post hoc analysis of a phase 3 trial found that subcutaneous infliximab delivered consistent clinical and endoscopic benefits across disease locations—including the terminal ileum—during maintenance therapy. The findings suggest a more uniform treatment effect than many clinicians expect, while also raising questions about how these results will translate outside controlled trials. What surprised investigators most, and what still needs to be proven, is explored in this report from Healio.